LINC01616

Across TCGA pan-cancer cohorts, LINC01616 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of LINC01616’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LINC01616 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC01616 is over-expressed in tumor, although a few such as KIRC and LUAD show the opposite, repressed pattern.

KIRC, LUAD, and LUSC are the cancer types where LINC01616 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01616 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	−0.062	<.001	11	view →
LUAD	Female	All	−0.448	<.001	8	view →
LUSC	Female	All	−0.345	<.001	6	view →
UCEC	All	All	−0.165	.004	6	view →
BRCA	All	III,IV	−0.112	<.001	6	view →
KIRP	All	All	−0.042	<.001	6	view →
COAD	All	II,III,IV	−0.016	<.001	5	view →
KICH	All	All	−0.038	.008	4	view →
PRAD	All	All	−0.050	.016	2	view →
ESCA	All	All	−0.043	.043	1	view →
THCA	Female	II,III,IV	−0.011	.013	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

LINC01616–KIRC

Open the KIRC breakdown →